A structural analysis of glycosaminoglycans from lethal and nonlethal breast cancer tissues: Toward a novel class of theragnostics for personalized medicine in oncology?

OMICS A Journal of Integrative Biology

Volumn 16, Issue 3, 2012, Pages 79-89

  Weyers, Amanda ^a   Yang, Bo ^a   Yoon, Dae Sung ^b   Park, Jong Hwan ^b   Zhang, Fuming ^c   Lee, Kyung Bok ^b   Linhardt, Robert J ^a,c,d  

^a Research Rensselaer Polytechnic Institute   (United States)

^b Konyang University   (South Korea)

^c RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^d RENSSELAER POLYTECHNIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISACCHARIDE; GLYCOSAMINOGLYCAN;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MOLECULAR WEIGHT; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SULFATION;

BREAST NEOPLASMS; CHROMATOGRAPHY, LIQUID; FEMALE; GLYCOSAMINOGLYCANS; HUMANS; INDIVIDUALIZED MEDICINE; MASS SPECTROMETRY;

EID: 84859799784     PISSN: 15362310     EISSN: 15578100     Source Type: Journal    
DOI: 10.1089/omi.2011.0102     Document Type: Article

References (56)

1. Alini, M., and Losa, G.A. (1991). Partial characterization of proteoglycans isolated from neoplastic and nonneoplastic human breask tissues. Cancer Res. 51, 1443-1447
2. Bishop, J.R., Schuksz, M., and Esko, J.D. (2007). Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446, 1030-1037 (Pubitemid 46676065)
3. Bitter, T., and Muir, H.M. (1962). A modified uronic acid carbazole reaction. Anal. Biochem. 4,330
4. Blackhall, F.H., Merry, C.L.R., Davies, E.J., and Jayson, G.C. (2001). Heparan sulfate proteoglycans and cancer. Br. J. Cancer 85, 1094-1098 (Pubitemid 33052304)
5. Bulow, H.E., and Hobert, O. (2006). The molecular diversity of glycosaminoglycans shapes animal development. Annu. Rev. Cell Dev. Biol. 22, 375-407
6. Corte, M.D., Gonzalez, L.O., Lamelas, M.L., Alvarez, A., Junquera, S., Allende, M.T., et al.. (2006). Expression and clinical signification of cytosolic hyaluronan levels in invasive breast cancer. Breast Cancer Res. Treat. 97, 329-337 (Pubitemid 43945763)
7. Corte, M.D., Gonzalez, L.O., Junquera, S., Bongera, M., Allende, M.T., and Vizoso, F.J. (2010). Analysis of the expression of hyaluronan in intraductal and invasive carcinomas of the breast. J. Cancer Res. Clin. Oncol. 136, 745-750
8. Delehedde, M., Deudon, E., Boilly, B., and Hondermarck, H. (1996). Heparan sulfate proteoglycans play a dual role in regulating fibroblast growth factor-2 mitogenic activity in human breast cancer cells. Exp. Cell Res. 229, 398-406 (Pubitemid 27026930)
9. Dietrich, C.P., Sampaio, L.O., and Toledo, O.M.S. (1976). Characteristic distribution of sulfated mucopolysaccharides in different tissues and in their respective mitochondria. Biochem. Biophys. Res. Commun. 71, 1-10
10. Dietrich, C.P., Sampaio, L.O., Toledo, O.M.S., and Cassaro, C.M.F. (1977). Cell recognition and adhesiveness-possible biological role for sulfated mucopolysaccharides. Biochem. Biophys. Res. Commun. 75, 329-336 (Pubitemid 8077277)
11. Edens, R.E., Alhakim, A., Weiler, J.M., Rethwisch, D.G., Fareed, J., and Linhardt, R.J. (1992). Gradient polyacrylamide gel electrophoresis for determination of molecular weights of heparin preparations and low molecular weight heparin derivatives. J. Pharm. Sci. 81, 823-827 (Pubitemid 23006826)
12. Esko, J.D., and Selleck, S.B. (2002). Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu. Rev. Biochem. 71, 435-471 (Pubitemid 34800227)
13. Fjeldstad, K., and Kolset, S.O. (2005). Decreasing the metastatic potential in cancers-targeting the heparan sulfate proteoglycans. Curr. Drug Targets 6, 665-680
14. Fujii, M., Yusa, A., Yokoyama, Y., Kokuryo, T., Tsunoda, N., Oda, K., et al.. (2010). Cytoplasmic expression of the JM403 antigen GlcA-GlcNH(3)( + ) on heparan sulfate glycosaminoglycan in mammary carcinomas-a novel proliferative biomarker for breast cancers with high malignancy. Glycoconj. J. 27, 661-672
15. Godavarti, R., Davis, M., Venkataraman, G., Cooney, C., Langer, R., and Sasisekharan, R. (1996). Heparinase III from Flavobacterium heparinum: cloning and recombinant expression in Escherichia coli. Biochem. Biophys. Res. Commun. 225, 751-758 (Pubitemid 26319178)
16. Gotte, M., and Yip, G.W. (2006). Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res. 66, 10233-10237 (Pubitemid 44799736)
17. Gressner, A.M. (1983). Hepatic proteoglycans-a brief survey of their patho-biochemical implications. Hepato-Gastroenterology 30, 225-229
18. Guo, C.H., Koo, C.Y., Bay, B.H., Tan, P.H., and Yip, G.W. (2007). Comparison of the effects of differentially sulphated bovine kidney- and porcine intestine-derived heparan sulphate on breast carcinoma cellular behaviour. Int. J. Oncol. 31, 1415-1423
19. Herrera-Gayol, A., and Jothy, S. (2001). Effects of hyaluronan on the invasive properties of human breast cancer cells in vitro. Int. J. Exp. Pathol. 82, 193-200 (Pubitemid 32718499)
20. Irimura, T., Nakajima, M., and Nicolson, G.L. (1986). Chemically modified heparins as inhibitors of heparan-sulfate specific endo-beta-glucurongdase (heparanase) of metastatic melanomacells. Biochemistry 25, 5322-5328 (Pubitemid 17016547)
21. Itano, N., and Kimata, K. (2008). Altered hyaluronan biosynthesis in cancer progression. Semin. Cancer Biol. 18, 268-274
22. Knutson, J. R., Iida, J., Fields, G.B., and McCarthy, J.B. (1996). CD44/chondroitin sulfate proteoglycan and alpha 2 beta 1 integrin mediate human melanoma cell migration on type IV collagen and invasion of basement membranes. Mol. Biol. Cell 7, 383-396 (Pubitemid 26089656)
23. Koo, C.Y., Bay, B.H., Lui, P.C.W., Tse, G.M.K., Tan, P.H., and Yip, G.W.C. (2006). Immunohistochemical expression of heparin sulfate correlates with stromal cell proliferation in breast phyllodes tumors. Modern Pathol. 19, 1344-1350
24. Kramer, M.W., Golshani, R., Merseburger, A.S., Knapp, J., Garcia, A., Hennenlotter, J., et al.. (2010). HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. Eur. Urol. 57, 86-93
25. Lee, C.M., Tanaka, T., Murai, T., Kondo, M., Kimura, J., Su, W., et al.. (2002). Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res. 62, 4282-4288 (Pubitemid 34827283)
26. Levy-Adam, F., Ilan, N., and Vlodavsky, I. (2010). Tumorigenic and adhesive properties of heparanase. Semin. Cancer Biol. 20, 153-160
27. Linhardt, R.J., and Toida, T. (2004). Role of glycosaminoglycans in cellular communication. Acc. Chem. Res. 37, 431-438
28. Lokeshwar, V.B., Obek, C., Soloway, M.S., and Block, N.L. (1997). Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. Cancer Res. 57, 773-777 (Pubitemid 27085665)
29. Lokeshwar, V.B., Young, M.J., Goudarzi, G., Iida, N., Yudin, A.I., Cherr, G.N., et al.. (1999). Identification of bladder tumorderived hyaluronidase: its similarity to HYAL1. Cancer Res. 59, 4464-4470 (Pubitemid 29418770)
30. Lokeshwar, V.B., Rubinowicz, D., Schroeder, G.L., Forgacs, E., Minna, J.D., Block, N.L., et al.. (2001). Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J. Biol. Chem. 276, 11922-11932
31. Lv, H.Z., Yu, G.L., Sun, L.L., Zhang, Z., Zhao, X., and Chai, W.G. (2007). Elevate level of glycosaminoglycans and altered sulfation pattern of chondroitin sulfate are associated with differentiation status and histological type of human primary hepatic carcinoma. Oncology 72, 347-356 (Pubitemid 351238149)
32. Mellor, P., Harvey, J.R., Murphy, K.J., Pye, D., O'Boyle, G., Lennard, T.W.J., et al.. (2007). Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo. Br. J. Cancer 97, 761-768 (Pubitemid 47396282)
33. Muramatsu, T., and Muramatsu, H. (2008). Glycosaminoglycanbinding cytokines as tumor markers. Proteomics 8, 3350-3359
34. Nakajima, M., Irimura, T., Diferrante, D., Diferrante, N., and Nicolson, G.L. (1983). Heparan-sulfate degradation-relation to tumor invasive and metastatic properties of mouse B-16 melanoma sublines. Science 220, 611-613 (Pubitemid 13130144)
35. Nurcombe, V., Smart, C.E., Chipperfield, H., Cool, S.M., Boilly, B., and Hondermarck, H. (2000). The proliferative and migratory activities of breast cancer cells can be differentially regulated by heparan sulfates J. Biol. Chem. 275, 30009-30018
36. Paiva, P., Van Damme, M.P., Tellbach, M., Jones, R.L., Jobling, T., and Salamonsen, L.A. (2005). Expression patterns of hyaluronan, hyaluronan synthases and hyaluronidases indicate role for hyaluronan in the progression of endometrial cancer. Gynecol. Oncol. 98 193-202 (Pubitemid 41019105)
37. Pham, H.T., Block, N.L., and Lokeshwar, V.B. (1997). Tumorderived hyaluronidase: a diagnostic urine marker for high grade bladder cancer. Cancer Res. 57, 778-783 (Pubitemid 27085666)
38. Platt, V.M., and Szoka, F.C. (2008). Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol. Pharmaceut. 5, 474-486
39. Ricciardelli, C., Mayne, K., Sykes, P.J., Raymond, W.A., McCaul, K., Marshall, V.R., et al.. (1997). Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer. Clin. Cancer Res. 3, 983-992 (Pubitemid 27252948)
40. Ricciardelli, C., Quinn, D.I., Raymond, W.A., McCaul, K., Sutherland, P.D., Stricker, P.D., et al.. (1999). Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for earlystage prostate cancer. Cancer Res. 59, 2324-2328 (Pubitemid 29242276)
41. Sakko, A.J., Butler, M.S., Byers, S., Reinboth, B.J., Stahl, J., Kench, J.G., et al.. (2008). Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse. Cancer Epidemiol. Biomarkers Prevent. 17, 2488-2497
42. Sampaio, L.O., Dietrich, C.P., and Filho, O.G. (1977). Changes in sulfated mucopolysaccharide composision of mammaliantissues during growth and in cancer tissues. Biochim. Biophys. Acta 498, 123-131 (Pubitemid 8117483)
43. Sasisekharan, R., Shriver, Z., Venkataraman, G., and Narayanasami, U. (2002). Roles of heparan-sulphate glycosaminoglycans in cancer. Nat. Rev. Cancer 2, 521-528 (Pubitemid 37328933)
44. Schonherr, E., Jarvelainen, H.T., Kinsella, M.G., Sandell, L.J., and Wight, T.N. (1993). Platelet-derived growth-factor and transforming growth-factor-beta-1 differentially affect the syntesis of biglycan and decorin by monkey arterial smooth-muscle cells. Arterioscler. Thromb. 13, 1026-1036 (Pubitemid 23195805)
45. Shaya, D., Tocilj, A., Li, Y.G., Myette, J., Venkataraman, G., Sasisekharan, R., et al.. (2006). Crystal structure of heparinase II from Pedobacter heparinus and its complex with a disaccharide product. J. Biol. Chem. 281, 15525-15535 (Pubitemid 43855145)
46. Simpson, M.A., Wilson, C.M., and McCarthy, J.B. (2002). Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. Am. J. Pathol. 161, 849-857 (Pubitemid 34988372)
47. Solakyildirim, K., Zhang, Z.Q., and Linhardt, R.J. (2010). Ultraperformance liquid chromatography with electrospray ionization ion trap mass spectrometry for chondroitin disaccharide analysis. Anal. Biochem. 397, 24-28
48. Teng, Y.H.F., Tan, P.H., Chia, S.J., Zam, N., Lau, W.K.O., Cheng, C.W.S., et al.. (2008). Increased expression of non-sulfated chondroitin correlates with adverse clinicopathological parameters in prostate cancer. Mod. Pathol. 21, 893-901 (Pubitemid 351896665)
49. Toida, T., Yoshida, H., Toyoda, H., Koshishi, I., Imanari, T., Hileman, R.E., et al.. (1997). Structural differences and the presence of unsubstituted amino groups in heparan sulphates from different tissues and species. Biochem. J. 322, 499-506 (Pubitemid 27116576)
50. Vizoso, F.J., del Casar, J.M., Corte, M.D., Garcia, I., Corte, M.G., Alvarez, A., et al.. (2004). Significance of cytosolic hyaluronan levels in gastric cancer. Eur. J. Surg. Oncol. 30, 318-324 (Pubitemid 38425652)
51. Vlodavsky, I., Friedmann, Y., Elkin, M., Aingorn, H., Atzmon, R., Ishai-Michaeli, R., et al.. (1999). Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis. Nat. Med. 5, 793-802 (Pubitemid 29318614)
52. Westling, C., and Lindahl, U. (2002). Location of N-unsubstituted glucosamine residues in heparan sulfate. J. Biol. Chem. 277, 49247-49255 (Pubitemid 36018720)
53. Yang, B., Weyers, A., Baik, J.Y., Sterner, E., Sharfstein, S., Mousa, S.A., et al.. (2011). Ultra-performing ion-pairing liquid chromatography with on-line electrospray ion trap mass spectrometry for heparin disaccharide analysis. Anal. Biochem. 415, 59-66
54. Yip, G.W., Smollich, M., and Gotte, M. (2006). Therapeutic value of glycosaminoglycans in cancer. Mol. Cancer Res. 5, 2139-2148 (Pubitemid 44530449)
55. Yoshida, E., Arakawa, S., Matsunaga, T., Toriumi, S., Tokuyama, S., Morikawa, K., et al.. (2002). Cloning, sequencing, and expression of the gene from Bacillus circulans that codes for heparinase that degrades both heparin and heparan sulfate. Biosci. Biotechnol. Biochem. 66 1873-1879 (Pubitemid 39246794)
56. Zhang, F.M., Sun, P.L., Munoz, E., Chi, L.L., Sakai, S., Toida, T., et al.. (2006). Microscale isolation and analysis of heparin from plasma using an anion-exchange spin column. Anal. Biochem. 353, 284-286 (Pubitemid 43792340)